Treatment of ecchymoses in skin of color with a 650-μs 1064-nm:YAG laser Authors: Raveena Khanna, Justin Morency, Cheri N Frey Published: 2026 Introduction Dermatologic patients frequently request treatment of cutaneous vascular lesions for both cosmetic and medical reasons. Laser-based energy devices are commonly used for management, as certain devices effectively target oxyhemoglobin in blood vessels, with thermal energy inducing vessel wall damage, coagulation, and absorption by the body.1 Pulsed dye lasers (PDLs) and potassium titanyl phosphate (KTP) lasers are the most commonly employed for conditions such as rosacea, port-wine stains (PWS), hemangiomas, and often postprocedural bruising as well. For patients of color, however, melanin is a competing chromophore at shorter wavelengths, which commonly results in dyspigmentation.1,2 The 650-μs, 1064-nm Nd:YAG laser has been safely used in this population for a wide range of indications; however, with a shorter pulse duration than the thermal relaxation time of skin tissue, this laser has proven to be a safer option in patients with darker skin types.3 Given the concern when treating vascular lesions in darker skin types, we herein sought to assess the efficacy of a 650-ms 1064-nm Nd:YAG laser for the treatment of ecchymosis in patients of color. Methods Three female patients, Fitzpatrick skin type (FST) III, IV, and VI, who presented with ecchymosis at the upper arm, chin, and antecubital fossa, respectively, all consented to laser treatment. The treated areas were cleansed with alcohol and treated with one session of the 650-μs, 1064-nm Nd:YAG laser (Neo Elite, Aerolase Corp.). A 6-mm lens with fluence of 14 J/cm2 (with settings 4.0 energy, 2.0 frequency, and 0.60 beam profile) was used to perform 2 passes in a cross-hatch pattern across affected sites. Photos were taken on initial presentation before treatment and 2 days after laser treatment to assess for improvement. Case 1: A 32-year-old Asian female, FST III, presented to clinic for laser treatment of ecchymoses secondary to injury at the left upper arm before treatment (left) and 3 days after treatment (right) (Fig 1). A 34-year-old Asian female, Fitzpatrick skin type IV, presented to clinic for laser treatment of ecchymoses secondary to dermal filler injections at the chin before treatment (left) and 3 days after treatment (right). Case 2: A 34-year-old Asian female, FST IV, presented to clinic for laser treatment of ecchymoses secondary to dermal filler injections at the chin before treatment (left) and 3 days after treatment (right) (Fig 2). A 32-year-old Asian female, Fitzpatrick skin type III, presented to clinic for laser treatment of ecchymoses secondary to injury at left upper arm before treatment (left) and 3 days after treatment (right). Case 3: A 47-year-old African American female, FST VI, presented to clinic for laser treatment of ecchymoses secondary to blood draw procedure at the left antecubital fossa before treatment (left) and 2 days after treatment (right) (Fig 3). ∗Of note, the treatment site is denoted as the area within the demarcated red box. The surrounding sites did not receive laser treatment. A 47-year-old African American female, Fitzpatrick skin type VI, presented to clinic for laser treatment of ecchymoses secondary to blood draw procedure at the left antecubital fossa before treatment (left) and 2 days after treatment (right). ∗Of note, the treatment site is denoted as the area within the demarcated red box. The surrounding sites did not receive laser treatment. All 3 patients saw significant reduction in bruising and associated pain within 48 hours of the laser procedure and noted complete resolution within 3 to 7 days of treatment. None of the patients reported any associated side effects of blistering or hyperpigmentation. All 3 patients found the procedure tolerable without the use of cooling. Conclusions Our findings show that the 650-μs 1064-nm Nd:YAG laser is a safe and effective treatment for ecchymoses in patients with skin of color, a population at an increased risk of hyperpigmentation when using vascular laser technology. All treated sites saw resolution of cutaneous bruising within 3 to 7 days of treatment, as compared with typical spontaneous recovery—which is expected somewhere between 10 and 14 days.4 Our results corroborate findings from a recent report of 6 adults (FST IV-VI) who saw 80% improvement in bruising after 72 hours of treatment with a 1064-nm long-pulsed Nd:YAG laser, and complete resolution after 1 week.5 Among laser-based energy devices, the 1064-nm Nd:YAG laser is preferred when treating patients of color, since its higher wavelength allows deeper penetration to hair bulbs, vessels, and dermal pigment, while minimizing epidermal heating.5,6 Still, the majority of data evaluates its utility for laser hair removal in skin of color, with few studies investigating the treatment of vascular lesions in this patient population. One study that explored the use of pulse dye laser in the treatment of PWS in pigmented skin showed higher incidences of atrophic scarring and postinflammatory hyperpigmentation.2 Another retrospective analysis of 261 Chinese patients (FST II-III) with PWS demonstrated that treatment with the 595-nm PDL was more successful in the youngest age group, hypothesizing that these findings may be attributed to thinner skin, less epidermal melanin, and less collagen among younger patients.7 Currently, however, there is a paucity of data for the safety and efficacy in patients with FST IV to VI, leaving fewer available options for the treatment of vascular lesions in this patient population. One study of 14 patients (7 of whom had FST III-IV) found that the long pulse 532-nm Nd:YAG laser was more effective in treating superficial bright red facial PWS as compared to the long pulse 1064-nm Nd:YAG device, with the majority of patients showing no recurrence, scarring, or hyperpigmentation at 3 months of follow-up.8 Another retrospective single-center study which included 16 patients with capillary and venous malformations demonstrated successful treatment after using the 532-nm KTP laser in conjunction with the long-pulsed 1064-nm Nd:YAG laser, noting 51% to 75% improvement in color, elevation, and texture.9 This study chose a combination approach rather than PDL or KTP laser alone due to their inability to penetrate at the depth required for deeper vascular lesions. The present study used the 650-μs 1064-nm Nd:YAG laser, which is commonly used in the treatment of melasma in skin-of-color patients, due to its ability to generate the least amount of heat and thereby decrease rebound pigmentation as compared to the Q-switched short-pulse and long-pulse Nd:YAG devices.10 Thus far, there is no literature examining its utility for ecchymoses or other vascular anomalies in patients of color, making our study among the first to demonstrate treatment success with this shorter-pulsed laser. Future studies may therefore seek to evaluate treatment response across other types of cutaneous vascular lesions in FST IV to VI, including PWS, infantile hemangiomas, rosacea, and venous malformations present across age groups. Conflicts of interest None disclosed. Footnotes Funding sources: None. Patient consent: The authors attest that they have obtained written consent from patient/s, their legal guardian/s or person/s with legal authority, for their photographs and medical information to be published in print and online and with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but are retained by the authors to be made available upon request. IRB approval status: Approval not required. References